dc.contributor.author | Davidson, Isobel | |
dc.contributor.author | Fyfe, Lorna | |
dc.date.accessioned | 2018-06-29T21:34:29Z | |
dc.date.available | 2018-06-29T21:34:29Z | |
dc.date.issued | 2016-05-20 | |
dc.identifier | ER4363 | |
dc.identifier.citation | Davidson, I. & Fyfe, L. (3916) A Randomised Double Blind Placebo Controlled Trial of a Nucleotide-Containing Supplement Nucell on Symptoms of Participants with the Common Cold - A Pilot Study, EC Nutrition. | |
dc.identifier.uri | https://www.ecronicon.com/ecnu/pdf/ECNU-04-0000112.pdf | |
dc.identifier.uri | https://eresearch.qmu.ac.uk/handle/20.500.12289/4363 | |
dc.description.abstract | Objectives: To ascertain whether a nucleotide containing nutritional supplement Nucell attenuates self-reported symptoms of the common cold.
Design: A randomised controlled trial.
Setting: A University.
Participants: Participants with self-reported symptoms of the common cold but otherwise healthy individuals.
Intervention: Nucell capsules containing a yeast-based nucleotide preparation or placebo were provided over a 28 day period.
Outcome Measures: Subjective ratings of symptoms were recorded by self-administered questionnaires using a nine-point scale. Salivary IgA concentrations were analysed from samples collected during the first 7 days and then at days 14,21 and 28 of supplementation. Total and white blood cell counts were also measured throughout the intervention.
Results: Thirty-six participants completed the study. Nineteen received Nucell and 17 received the placebo. The mean age of participants was similar (29.8 + 2.5 in Nucell group v 30.7 + 2.7 in control group) and the time participants had been suffering from cold-related symptoms was not significantly different in each treatment group (2.5 + 0.40 days in Nucell v 2.9 + 0.47 days in control group). Severity of self-reported symptoms was significantly attenuated in the Nucell treated group in the first week of supplementation for questions asked with respect to taste, painful sinuses and earache (p< 0.05). Supplementation with Nucell did not adversely affect total or differential white blood counts.
Conclusion: These results suggest that Nucell supplementation administered as a treatment for cold-related symptoms may reduce the severity of specific symptoms particularly in the early infective phase. In conclusion, Nucell supplementation may provide subjective relief of some cold-related symptoms and may be of significant benefit administered as a treatment in participants where sinus pain, earache and diminished taste are common symptoms. | |
dc.publisher | ECronicon | |
dc.relation.ispartof | EC Nutrition | |
dc.title | A Randomised Double Blind Placebo Controlled Trial of a Nucleotide-Containing Supplement Nucell on Symptoms of Participants with the Common Cold - A Pilot Study | |
dc.type | article | |
dcterms.accessRights | public | |
dc.description.faculty | sch_die | |
dc.description.ispublished | pub | |
dc.description.eprintid | 4363 | |
rioxxterms.type | article | |
refterms.dateAccepted | 2016-05-17 | |
qmu.author | Fyfe, Lorna | |
qmu.author | Davidson, Isobel | |
qmu.centre | Centre for Health, Activity and Rehabilitation Research | |
dc.description.status | pub | |